SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Maulcoin

Maulcoin is capturing attention as a community-driven meme project that is consistently trending on social platforms without an official chart, fueling intense community speculation about an upcoming breakout. Holders are actively discussing milestone targets for market capitalization and expressing strong commitment to the project's long-term growth and cultural branding.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs shares are facing selling pressure as investors react to the resignation of the firm's top lawyer over ties to Jeffrey Epstein. The community is actively debating the implications of these reputational risks while technical traders monitor the stock's recent break below key support levels.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending as investors digest strong topline results from its Phase 3 RASolute 302 clinical trial, triggering significant price appreciation and active discussion regarding the company's future as a potential buyout target. Community sentiment remains highly bullish, with many highlighting the stock's robust cash position and the transformative potential of its daraxonrasib treatment for pancreatic cancer.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors react to the company securing over $4 million in government contracts for quantum materials and lasers, sparking a debate between those betting on long-term technological validation and those skeptical of the company's path to high-volume commercialization. Community discourse is heavily focused on the stock's low float and short interest, fueling speculation of potential volatility and high-reward upside as the company aims to scale its semiconductor integration platform for AI and defense applications.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing intense market volatility driven by a massive short squeeze that has triggered a cascade of liquidations for traders betting against the token. The community is actively debating the project's rapid valuation growth and its potential as a decentralized music entertainment protocol, with many highlighting recent exchange listings and upcoming event roadmap milestones as catalysts for continued momentum.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and heightened scrutiny as traders debate whether current valuation levels represent a sustainable AI-driven growth cycle or an overheated bubble. The community is actively tracking a sharp divergence between high-flying hardware momentum and a struggling software sector, while aggressive options activity and short-dated put sweeps suggest that institutional players are bracing for significant downside risks.

Cloudflare, Inc. engages in the provision of cloud-based services to secure websites. It offers various products for performance and reliability, video streaming and delivery, advanced security, insights, Cloudflare for developers, domain registration, and Cloudflare marketplace. It operates through the United States and Rest of the World geographical segments. The company was founded by Matthew Prince, Michelle Zatlyn, and Lee Holloway in July 2009 and is headquartered in San Francisco, CA.

Cloudflare Inc - Ordinary Shares - Class A

Cloudflare Inc

Cloudflare is generating significant investor buzz following a strong quarterly earnings report that surpassed revenue estimates, highlighting its essential role in the expanding AI-driven infrastructure sector. The community is actively debating the company's long-term growth potential and its ability to capitalize on rising internet traffic and edge computing demand despite recent sector-wide volatility and AI-related disruption narratives.

Roblox Corp. engages in the provision of online gaming services. Its platform consists of Roblox Client, Roblox Studio, and Roblox Cloud. Roblox Client is an application that allows users to explore 3D digital worlds. Roblox Studio is the toolset that allows developers and creators to build, publish, and operate 3D experiences and other content accessed with Roblox Client. Roblox Cloud includes the services and infrastructure that power the human co-experience platforms. The company was founded by Erik Cassel and David B. Baszucki in March 2004 and is headquartered in San Mateo, CA.

Roblox Corporation - Ordinary Shares - Class A

Roblox Corp.

Roblox is experiencing significant volatility and heightened trading volume as investors react to a stronger-than-expected earnings report, with community sentiment split between technical buy-the-dip strategies and ongoing skepticism regarding regulatory risks and company governance.

ImageneBio, Inc. is a clinical-stage biotechnology company that boldly imagines a world where patients can be free from the burden of grievous immunological/autoimmune and inflammatory (I&I) diseases. It focuses on the development of new medicines with differentiated profiles that can effectively control and change the course of I&I diseases for affected patients, treat their symptoms, and improve quality of life. The company was founded in February 2016, and is headquartered in San Diego, CA.

ImageneBio Inc.

ImageneBio, Inc.

ImageneBio, Inc. is trending as investors weigh significant institutional backing and cash-rich financials against long-term development timelines for its lead drug candidates targeting atopic dermatitis and alopecia. The community is actively debating the potential for a technical breakout amid high volatility, with many focused on how the company's valuation compares to its cash reserves and pipeline potential.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a volatile spotlight following a combination of a high-profile endorsement from Donald Trump and intense short-selling pressure from investors like Michael Burry. The community remains deeply divided, with bulls pointing to the company's critical role in military AI and defense contracts, while bears raise significant concerns regarding its current valuation and rising competition from alternative AI models.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 RGNX UPCOMING DEADLINE: Faruqi & Faruqi, LLP Reminds REGENXBIO...

RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit

RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit RGNX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit PR Newswire NEW YORK, April 9, 2026...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX INVESTOR ALERT: Pomerantz Law Firm Reminds...

RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm

RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline in REGENXBIO Inc. Securities Class Action Lawsuit -- The Gross Law Firm RGNX Shareholder Alert: April 14, 2026 Lead Plaintiff Deadline...

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm

RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the Schall Law Firm RGNX Investors Have Opportunity to Lead REGENXBIO Inc. Securities Fraud Lawsuit with the...

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX

REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - RGNX REGENXBIO Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss...

RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026

RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO (RGNX) Investors of Securities Class Action Deadline on April 14, 2026 RGNX SHAREHOLDER ALERT: Faruqi & Faruqi, LLP Reminds REGENXBIO...

REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights

REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights REGENXBIO, Inc. Class Action Reminder - Robbins LLP Encourages RGNX Stockholders to Contact the Firm for Information About Their Rights PR Newswire SAN DIEGO...

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming Deadlines - RGNX INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in REGENXBIO Inc. of Class Action Lawsuit and Upcoming...

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP

STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY, LLP STEPHEN PAKOLA OVERSAW RGX-111 SAFETY CLAIMS THAT COST RGNX INVESTORS MILLIONS: LEVI & KORSINSKY...

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include the NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors, and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Current Price	$8.90
Prev Close	$8.80
Open	$8.83
Dividend Yield	0.00%
50-Day Moving Average	$8.93
Beta	1.66
Avg. Volume	980,793.04
PE Ratio	-2.34

52-Week High	$16.19
52-Week Low	$5.81
Market Capitalization	$454.19M
EPS (Annual)	-$3.76
Price to Book	4.36
Revenue Per Employee	$459,409.70

RGNX
Regenxbio Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest RGNX News

RGNXRegenxbio Inc